ProShares Ultra Nasdaq Biotechnology (BIB) Annual Income Statement (USD)
BIB Quarterly Financials (USD)
Frequently Asked Questions About ProShares Ultra Nasdaq Biotechnology (BIB) Stock
ProShares Ultra Nasdaq Biotechnology's (BIB) last reported annual revenue was N/A.
ProShares Ultra Nasdaq Biotechnology's (BIB) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
ProShares Ultra Nasdaq Biotechnology's(BIB) is not profitable as of its last reported annual financials.
The net profit margin for ProShares Ultra Nasdaq Biotechnology's(BIB) from its laster reported year is N/A
The return on equity (ROE) for ProShares Ultra Nasdaq Biotechnology's(BIB) from its last reported annual financials is : N/A
The return on assets (ROA) for ProShares Ultra Nasdaq Biotechnology's(BIB) from its last reported annual financials is : N/A
The return on invested capital (ROIC) for ProShares Ultra Nasdaq Biotechnology's(BIB) from its last reported annual financials is : 0.00%
The Debt to Equity ratio for ProShares Ultra Nasdaq Biotechnology's(BIB) from its last reported annual financials is : 0.00%
The dividend yield for ProShares Ultra Nasdaq Biotechnology's(BIB) from its laster reported year is 0.83%
ProShares Ultra Nasdaq Biotechnology's(BIB) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
